Unit for Neurosciences Nursing demonstrates AMC21 quality pillar goal
- Created on November 22, 2013
When it comes to quality, the Unit for Neurosciences Nursing (UNSN) has continued to improve their performance by enacting the Reaching for Excellence principles into their routine. Nurse Manager Elizabeth Toomey (pictured, right) attributes her team's success to their commitment to holding each other accountable to these daily practices, whether it is hourly rounding, hand washing, or other common practices to improve quality for patients.
"I expect people to do their jobs, and we hold each other accountable if they don't," Toomey states.
For example, Toomey's unit took it upon themselves to reduce the number of patient falls, and began to brainstorm on ways to reduce them. Advanced Nursing Coordinator Dorri Bierley (pictured, left) initiated different practices, such as daily safety huddles, staff education, and documentation audits. The daily safety huddles between Registered Nurses (RNs) and Patient Care Technicians (PCTs) are used to discuss which patients are at risk for falling and those who have particular issues the staff needs to be aware of in order to best serve the patient. Bierley states that maintaining a high level of quality care begins with staff awareness of quality issues that need to be addressed daily.
"Everything is incorporated into the safety huddles every morning because good quality is what our patients expect of us," explains Toomey.
UNSN also began hourly rounding with patients, as recommended by Reaching for Excellence, as evidence demonstrates that this practice reduces the number of times patients call for assistance with their ‘call lights.' Since hardwiring this behavior into their routine, UNSN has seen a decrease in these calls and a significant decrease in their patient fall rate.
Bierley adds that Toomey always stresses to their team to treat patients as if they are family members in the hospital. "There is a direct correlation to quality when you treat patients like family members, everything goes up from there."
Toomey attributes their success to the staff's longevity and dedication to the unit; little staff turnover makes it easier to create a stable environment. Plus, they maintain a sense of team, always willing to help if someone needs it. Bierley acknowledges that the recognition of staff members' performance is a contributing factor to the lack of turnover, praising Toomey for her dedication to acknowledge a nurse who goes above and beyond.
"If a patient tells me someone has done a great job, I will call their names out in staff meetings and give them a ‘Fantastic Five' card to reward them," says Toomey.
Fantastic Five cards are $5 cards that can be used in cafeterias and coffee shops throughout UAB. Toomey noted that residents and unit secretaries are also honored for going above and beyond the call of duty.
The main challenges facing UNSN now are the changes in health care and keeping nurses educated about new policies. It is a test for their unit because they experienced positive results from the old policies, but Toomey assures that her team will maintain their devotion to the highest quality.
"Our staff is very open to changing and adapting to handle things," says Toomey.
Chief Quality Officer for Inpatient Services, Ben Taylor, M.D., M.P.H., reiterates this dedication to quality throughout UAB and points out that UAB's quality measures are the highest they've ever been, in the context of a continually changing health care environment. UAB has to continue to work and evaluate practices in order to keep quality results high. "The whole point is to do more of what works and less of what doesn't, which sounds simple, but can be really hard in a big complex place like ours."
Toomey cannot give her team enough praise for their hard work over the last 3 years to improve quality. She praises their devotion to their patients and teamwork as their keys to success and states it best: quality and patient satisfaction go hand in hand.
Click here for more information on how to improve quality metrics with UAB's Reaching for Excellence.
$1 billion goal announced for UAB’s largest-ever fundraising campaign
- Created on October 28, 2013
The University of Alabama at Birmingham today officially kicked off the public phase of The Campaign for UAB: Give Something, Change Everything, the university’s largest fundraising campaign to date, announcing an ambitious $1 billion goal.
The campaign will run through 2018.
“The theme reflects the fact that, when you give to UAB, you help us change our community and our world for the better, whether by finding the cure for a disease, enabling a bright young person to go to college or lighting the spark for a new innovation,” UAB President Ray L. Watts said. “We are working hard to strengthen our position as one of the nation’s most productive and dynamic universities. To accomplish this goal, we are going to set our priorities, invest resources carefully and invite partners to join us.”
To see full article please click the below link:
UA team part of breakthrough research on Parkinson's disease
- Created on October 25, 2013
A team of scientists including researchers at the University of Alabama has identified a chemical compound that helps enhance a brain cell’s ability to combat the effects of blocks formed by a protein linked to Parkinson’s Disease.
The collaborative research was led by the Massachusetts Institute of Technology biology professor Susan Lindquist, along with researchers at UA, Harvard University, Purdue University and St. Jude Children’s Research Hospital.
To see full article click on the link below:
NeuroNEXT is pleased to announce funding for our third approved trial: "Rituximab in Myasthenia Gravis".
- Created on October 18, 2013
Richard J. Nowak, MD, MS, Yale University School of Medicine, is the Protocol Principal Investigator for the study “A Phase II Trial of Rituximab in Myasthenia Gravis” (NN103). Other primary investigators include Drs. Jonathan M. Goldstein, Richard J. Barohn, Mazen M. Dimachkie, Kevin C. O’Connor and David A. Hafler.
Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission with an estimated annual incidence of about 1-2 per 100,000 and prevalence as high as 20-50 per 100,000. Treatment consists of symptomatic therapy with acetylcholinesterase inhibitors and immunotherapy such as corticosteroids, azathioprine, cyclosporine, plasma exchange (PLEX) and intravenous immunoglobulin (IVIg). Despite current therapies a subset of patients remain medically refractory or have intolerable medication adverse effects. There is need for another agent in the management of MG as there are few effective drugs.
This research study is being conducted to determine the safety, tolerability and activity of rituximab administered in two four-week infusion cycles separated by six months in subjects with myasthenia gravis. The study will be conducted by the NINDS-funded Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) at NeuroNEXT sites around the United States. Fifty participants age 21 and older will be enrolled. The Clinical Coordination Center is at Massachusetts General Hospital and the Data Coordination Center is at the University of Iowa.
The following fifteen institutions have been selected to participate in the study:
Albert Einstein College of Medicine Yeshiva University
Weill Cornell Medical Center
Ohio State University
University of Alabama at Birmingham
University of California - Davis
University of California - Los Angeles
University of Cincinnati
University of Colorado Denver
University of Kansas Medical Center
University of Miami School of Medicine
University of Pittsburgh
University of Rochester
University of Texas Southwestern Medical Center
University of Virginia - Charlottesville
The study intervention is provided by Genentech Pharmaceuticals.
For more information related to the University of Alabama at Birmingham site please contact Shirley Gibbs at 205-975-0447.
- Alabama chicken farmer glad UAB will study mysterious muscle-twisting disease triggered in him by tornado
- Center of Excellence designation will boost dystonia research and care at UAB
- UAB researchers identify proteins that may help brain tumors spread
- UAB researcher searches for biomarkers for Lou Gehrig’s disease